Incorporating apolipoprotein L1 testing into evaluation of potential living kidney donors: a single-centre experience

Authors:

Abstract
Assessment of future risk of end-stage renal disease (ESRD) is an important component of evaluation of potential living kidney donors. Known donor risk factors for ESRD include first-degree relatives, young age, male sex and African descent [1]. In the general population, the presence of two apolipoprotein L1 (APOL1) risk alleles is a key determinant of the excess incidence of ESRD observed in African Americans [2]. In living kidney donors, the effect of the APOL1 genotype on the risk of developing ESRD is unknown. However, the higher risk in black donors and the faster decline in estimated glomerular filtration rate (eGFR) observed post-donation in donors with two APOL1 risk alleles [3] suggests that this group should be considered with caution. The APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) study (NCT03615235) aims to provide prospective data to guide these decisions in the future. In the current absence of prospective data, some centres screen for APOL1 risk alleles in potential donors of African descent. A recent survey of US transplant surgeons and physicians reported that 63% of them intended to use APOL1 testing in the next year [4]. Patient perspectives of APOL1 testing in potential donors are also supportive of this approach [5, 6]. The experience of a policy of testing APOL1 risk alleles in potential donors has not been previously reported.

This publication has 8 references indexed in Scilit: